Literature DB >> 26116328

Validation of the Spanish version of the Clinical Assessment for Negative Symptoms (CAINS).

Alicia Valiente-Gómez1, Gisela Mezquida2, Anna Romaguera3, Irene Vilardebò4, Helena Andrés5, Bianca Granados5, Jesús Larrubia5, Edith Pomarol-Clotet6, Peter J McKenna6, Salvador Sarró7, Miguel Bernardo8.   

Abstract

Negative symptoms are a core feature of schizophrenia and their reliable and valid assessment is a prerequisite for developing effective therapeutic interventions. This study examined the psychometric properties and validity of the Spanish version of a new rating instrument, the Clinical Assessment Interview for Negative Symptoms (CAINS). Outpatients and inpatients (N=100) with DSM-IV schizophrenia were administered the translated CAINS, the Positive and Negative Syndrome Scale (PANSS), the Scale for the Assessment of Negative Symptoms (SANS), and the Calgary Depression Scale for Schizophrenia (CDSS). A subsample (N=46) was rated for Parkinsonism using the Extrapyramidal Symptoms Rating Scale (ESRS). The scale showed good inter-rater and intra-rater reliability. Both the CAINS overall and the subscales for motivation/pleasure (CAINS-Map) and expression (CAINS-Exp) scores correlated significantly with the SANS and PANSS negative symptom scale. Significant correlations with positive symptoms and general psychopathology were also found, but these reduced and mostly became insignificant when overall severity of illness was controlled for. Significant correlations with depression also disappeared when severity was controlled for. There was a trend-level correlation between the CAINS total score and Parkinsonism, which reflected an association with the CAINS-Exp subscale only. Factor analysis revealed a two-dimensional structure that explained the 67.44% of the variance. Overall, the Spanish version of the CAINS appears to be a valid tool for measuring negative symptoms in schizophrenia.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Assessment; Negative symptoms; Rating scale; Schizophrenia; Validation

Mesh:

Year:  2015        PMID: 26116328     DOI: 10.1016/j.schres.2015.06.006

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  14 in total

1.  A Psychometric Comparison of the Clinical Assessment Interview for Negative Symptoms and the Brief Negative Symptom Scale.

Authors:  Gregory P Strauss; James M Gold
Journal:  Schizophr Bull       Date:  2016-05-12       Impact factor: 9.306

2.  Cognitive, community functioning and clinical correlates of the Clinical Assessment Interview for Negative Symptoms (CAINS) in psychotic disorders.

Authors:  Manuel J Cuesta; Ana M Sánchez-Torres; Ruth Lorente-Omeñaca; Lucía Moreno-Izco; Victor Peralta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-09-07       Impact factor: 5.270

3.  Bridge centrality network structure of negative symptoms in people with schizophrenia.

Authors:  Ling-Ling Wang; Michelle H W Tam; Karen K Y Ho; Karen S Y Hung; Jessica O Y Wong; Simon S Y Lui; Raymond C K Chan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-08-16       Impact factor: 5.760

4.  Validation of accelerometry as a digital phenotyping measure of negative symptoms in schizophrenia.

Authors:  Gregory P Strauss; Ian M Raugh; Luyu Zhang; Lauren Luther; Hannah C Chapman; Daniel N Allen; Brian Kirkpatrick; Alex S Cohen
Journal:  Schizophrenia (Heidelb)       Date:  2022-04-15

5.  Network Analysis Reveals the Latent Structure of Negative Symptoms in Schizophrenia.

Authors:  Gregory P Strauss; Farnaz Zamani Esfahlani; Silvana Galderisi; Armida Mucci; Alessandro Rossi; Paola Bucci; Paola Rocca; Mario Maj; Brian Kirkpatrick; Ivan Ruiz; Hiroki Sayama
Journal:  Schizophr Bull       Date:  2019-09-11       Impact factor: 9.306

6.  Cross Cultural Validation and Extension of the Clinical Assessment Interview for Negative Symptoms (CAINS) in the Chinese Context: Evidence from a Spectrum Perspective.

Authors:  Dong-Jie Xie; Hai-Song Shi; Simon S Y Lui; Chuan Shi; Ying Li; Karen K Y Ho; Karen S Y Hung; Wen-Xiu Li; Zheng-Hui Yi; Eric F C Cheung; Ann M Kring; Raymond C K Chan
Journal:  Schizophr Bull       Date:  2018-10-15       Impact factor: 9.306

7.  Validation of the French Clinical Assessment Interview for Negative Symptoms in a Sample of Stable French Individuals With Schizophrenia.

Authors:  Yasmine Laraki; Cindy Lebrun; Marine Merenciano; Margot Eisenblaetter; Jerôme Attal; Alexandra Macgregor; Amandine Decombe; Delphine Capdevielle; Stéphane Raffard
Journal:  Front Psychiatry       Date:  2022-04-01       Impact factor: 4.157

8.  A Two-Factor Model Better Explains Heterogeneity in Negative Symptoms: Evidence from the Positive and Negative Syndrome Scale.

Authors:  Seon-Kyeong Jang; Hye-Im Choi; Soohyun Park; Eunju Jaekal; Ga-Young Lee; Young Il Cho; Kee-Hong Choi
Journal:  Front Psychol       Date:  2016-05-12

9.  Validation of the Korean Version of the Clinical Assessment Interview for Negative Symptoms.

Authors:  Seon-Kyeong Jang; Seon-Cheol Park; Kee-Hong Choi; Jung-Seo Yi; Joong-Kyu Park; Jung Suk Lee; Seung-Hwan Lee
Journal:  Psychiatry Investig       Date:  2017-07-11       Impact factor: 2.505

10.  Cognitive impairment and C-reactive protein in clinically stable schizophrenia outpatients: a focus on sex differences.

Authors:  Francesco Dal Santo; Leticia González-Blanco; Leticia García-Álvarez; Lorena de la Fuente-Tomás; Ángela Velasco; Clara María Álvarez-Vázquez; Clara Martínez-Cao; Pilar A Sáiz; María Paz García-Portilla; Julio Bobes
Journal:  Sci Rep       Date:  2020-09-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.